The top 10 drugs losing US exclusivity in 2023
- Across the industry this year, big-selling drugs from Johnson & Johnson, Takeda, AstraZeneca, Roche and other companies are set to face their first generic or biosimilar challengers in the U.S. As always, the patent expirations should create quite a shake-up for many of the industry’s top players.
- Read more?here
Eli?Lilly to cut some list prices by 70% and offer $25 insulin
- Eli Lilly and Co?on Wednesday said it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from the fourth quarter of this year, a move that could help millions of Americans afford their medicine. The Indianapolis-based drugmaker also will lower the price of its Lispro insulin injection to $25 a vial and expand its insulin value program so that an existing $35 cap on some insulins will now apply in about 85% of U.S. pharmacies.
- Read more?here
Global Market Outlook On Stem Cell Manufacturing
- The stem cell manufacturing market is a rapidly growing industry and is expected to grow from $11.22 billion in 20221 to approximately $23.89 billion by 2030, with a compound annual growth rate of 11.2% over the forecasted period. It is a rapidly changing sector and is showing the most promise is in several sectors.
- Read more?here
If you are interested in any of these topics check out our online training courses led by TOP experts:
Project Management for Generics
Process Scale-up & Tech Transfer for Injectables
Good Manufacturing Practices in API Production: How to Implement ICHQ7
